Transgene Biotek (BOM:526139) EV-to-FCF: (As of Jul. 24, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:526139 Transgene Biotek Ltd BOM:526139
50 GF Score
Price ₹2.97
GF Value ₹6.61
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Transgene Biotek EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Transgene Biotek's Enterprise Value is ₹395.80 Mil. Transgene Biotek's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0.00 Mil. Therefore, Transgene Biotek's EV-to-FCF for today is .

The historical rank and industry rank for Transgene Biotek's EV-to-FCF or its related term are showing as below:

BOM:526139' s EV-to-FCF Range Over the Past 10 Years
Min: -3542.86   Med: 0   Max: 0
Current: -3542.86

BOM:526139's EV-to-FCF is ranked worse than
100% of 340 companies
in the Biotechnology industry
Industry Median: 14.79 vs BOM:526139: -3542.86

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-07-24), Transgene Biotek's stock price is ₹2.97. Transgene Biotek's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-0.220. Therefore, Transgene Biotek's PE Ratio (TTM) for today is At Loss.


Transgene Biotek  (BOM:526139) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Transgene Biotek's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2.97/-0.220
=At Loss

Transgene Biotek's share price for today is ₹2.97.
Transgene Biotek's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-0.220.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Transgene Biotek EV-to-FCF Related Terms


Transgene Biotek EV-to-FCF Historical Data

* Premium members only.

The historical data trend for Transgene Biotek's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Transgene Biotek EV-to-FCF Chart

Transgene Biotek Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 402.31 -24,597.02 16,450.02 -78.65 -2,838.80

Transgene Biotek Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -78.65 0.00 0.00 0.00 -2,838.80

BOM:526139 vs VRTX, REGN, ALNY: EV-to-FCF Comparison

For the Biotechnology subindustry, Transgene Biotek's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Transgene Biotek EV-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Transgene Biotek's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Transgene Biotek's EV-to-FCF falls into.


BOM:526139
50GF Score
Transgene Biotek Ltd BOM:526139
EV-to-FCF is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Transgene Biotek EV-to-FCF Calculation

Transgene Biotek's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=395.797/0
=

Transgene Biotek's current Enterprise Value is ₹395.80 Mil.
Transgene Biotek's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Transgene Biotek (BOM:526139) Overvalued in 2026?

Based on GuruFocus' analysis, Transgene Biotek stock appears to be undervalued. The current stock price of ₹2.97 is trading 55.1% below its estimated GF Value™ of ₹6.61. GuruFocus considers Transgene Biotek to be Possible Value Trap.

Key valuation signals for BOM:526139:

  • EV-to-FCF:
  • GF Value™: ₹6.61 vs. price of ₹2.97 (55.1% below fair value)
  • GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the BOM:526139 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Transgene Biotek Business Description

Address Anrich Industrial Area, Plot No. 69 and 70, IDA Bollaram, Sangareddy District, Medak, TG, IND, 502325
Transgene Biotek Ltd is an India-based research and development company. It is engaged in the research and development of molecules and technologies for the production of active pharmaceutical ingredients and other pharmaceutical products. The company is operating only in one segment of Bulk Drugs. Its product portfolio includes TrabiDHA, Tracolimus, and Orlistat. It generates revenue from the sale of goods and services.
50GF Score

Get the complete analysis for BOM:526139

EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2.97
Price
₹6.61
GF Value